1. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004;10(1):17-8.
  2. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974;125C(1-2):373-89.
  3. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev 1984;5(3):435-55.
  4. Paavonen T. Hormonal regulation of lymphocyte functions. Med Biol 1987;65(5-6):229-40.
  5. Snyder SH. Brain peptides as neurotransmitters. Science 1980;209(4460):976-83.
  6. O'Dorisio MS. Neuropeptides and gastrointestinal immunity. Am J Med 1986;81(6B):74-82.
  7. Cavagnaro J, Waterhouse GA, Lewis RM. Neuroendocrine-immune interactions: immunoregulatory signals mediated by neurohumoral agents. Year Immunol 1988;3:228-46.
  8. Dinarello CA. Interleukin-1. Ann N Y Acad Sci 1988;546:122-32.
  9. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990;59:783-836.
  10. Alm GV. Lymphokines in the regulation of immune responses. Vet Immunol Immunopathol 1987;17(1-4):173-82.
  11. Christopherson K, Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells 2001;19(5):388-96.
  12. Leibovitz B, Siegel BV. Ascorbic acid, neutrophil function, and the immune response. Int J Vitam Nutr Res 1978;48(2):159-64.
  13. Manolagas SC, Provvedini DM, Tsoukas CD. Interactions of 1,25-dihydroxyvitamin D3 and the immune system. Mol Cell Endocrinol 1985;43(2-3):113-22.
  14. Peelen E, Knippenberg S, Muris AH, Thewissen M, Smolders J, Tervaert JW, Hupperts R, Damoiseaux J. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011;10(12):733-43.
  15. Lewis RA. Interactions of eicosanoids and cytokines in immune regulation. Adv Prostaglandin Thromboxane Leukot Res 1990;20:170-8.
  16. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188(1):21-8.
  17. Kirschning CJ, Bauer S. Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 2001;291(4):251-60.
  18. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003;102(3):956-63.
  19. Nelson RP Jr, Ballow M. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 2003;111(2 Suppl):S720-43.
  20. Refojo D, Liberman AC, Giacomini D, Carbia Nagashima A, Graciarena M, Echenique C, Paez Pereda M, Stalla G, Holsboer F, Arzt E. Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells. Ann N Y Acad Sci 2003;992:196-204.
  21. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003;3(1):36-50.
  22. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001;62(2):111-23.
  23. Cavagnaro J. Molecular basis for the bidirectional modulation of the neuroendocrine and the immune systems. Year Immunol 1986;2:303-22.
  24. Kordon C, Bihoreau C. Integrated communication between the nervous, endocrine and immune systems. Horm Res 1989;31(1-2):100-4.
  25. Hall NR, O'Grady MP. Regulation of pituitary peptides by the immune system. Bioessays 1989;11(5):141-4.
  26. Tozzoli R. The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases. Clin Chem Lab Med 2008;46(5):577-87.
  27. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity--autoantibodies versus autoimmune disease. Autoimmun Rev 2010;9(5):A259-66.
  28. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF, Wakeland EK, Olsen NJ. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011;13(2):R38.
  29. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;363(9420):1544-6.
  30. Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011;13(1):R13.
  31. Shoenfeld Y, Blank M, Abu-Shakra M, et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases. 2008 IMAJ;10:13–19.
  32. Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009;29(3):241-53.
  33. Alaedini A, Green PH. Autoantibodies in celiac disease. Autoimmunity 2008;41(1):19-26.
  34. Fritzler MJ, Salazar M. Diversity and origin of rheumatologic autoantibodies. Clin Microbiol Rev 1991;4(3):256-69.
  35. da Mota LM, Dos Santos Neto LL, de Carvalho JF, Pereira IA, Burlingame R, Ménard HA, Laurindo IM. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years. Rheumatol Int 2011 Dec 21;DOI: 10.1007/s00296-011-2260-9.
  36. Miller A, Chan M, Wiik A, Misbah SA, Luqmani RA. An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol 2010;160(2):143-60.
  37. Borg AA. Antibodies to cytokeratins in inflammatory arthropathies. Semin Arthritis Rheum 1997;27(3):186-95.
  38. Brás A, Aguas AP. Mycobacteria-induced autoantibody production is associated with susceptibility to infection but not with host propensity to develop autoimmune disease. Clin Exp Immunol 1995;100(1):75-80.
  39. Ferrara F, Quaglia S, Caputo I, et al. Anti-transglutaminase antibodies in non-coeliac children suffering from infectious diseases. Clin Exp Immunol 2010;159(2):217-23.
  40. Hodgkin PD An antigen valence theory to explain the evolution and organization of the humoral immune response. Immunol Cell Biol 1997;75(6):604-18.
  41. Scott-Browne JP, Crawford F, Young MH, Kappler JW, Marrack P, Gapin L. Evolutionarily conserved features contribute to αβ T cell receptor specificity. Immunity 2011;35(4):526-35.
  42. O'Connell MJ, McInerney JO. Gamma chain receptor interleukins: evidence for positive selection driving the evolution of cell-to-cell communicators in the mammalian immune system. J Mol Evol 2005;61(5):608-19.
  43. Kasahara M, Suzuki T, Pasquier LD. On the origins of the adaptive immune system: novel insights from invertebrates and cold-blooded vertebrates. Trends Immunol. 2004;25(2):105-11.
  44. Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, Chronopoulou E, Trachana M. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine 2008;42(3):293-7.
  45. Posner JB. Immunology of paraneoplastic syndromes: overview. Ann N Y Acad Sci 2003;998:178-86.
  46. Thomas C, Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology 2010;278(2):204-10.
  47. de Bruyn G. Cofactors that may influence vaccine responses. Curr Opin HIV AIDS 2010;5(5):404-8.
  48. Thrasher JD, Broughton A, Madison R. Immune activation and autoantibodies in humans with long-term inhalation exposure to formaldehyde. Arch Environ Health 1990;45(4):217-23.
  49. El-Fawal HA, Waterman SJ, De Feo A, Shamy MY. Neuroimmunotoxicology: humoral assessment of neurotoxicity and autoimmune mechanisms. Environ Health Perspect 1999 Oct;107 Suppl 5:767-75.
  50. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–279.
  51. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010 Jun;5(3):193-200.
  52. Eccles JC. Excitatory and inhibitory synaptic action. Ann N Y Acad Sci 1959;81:247-64.
  53. von Euler US. Adrenergic neurotransmitter functions. Science 1971;173(3993):202-6.
  54. Schloesser R, Simkowitz P, Bartlett EJ, Wolkin A, Smith GS, Dewey SL, Brodie JD. The study of neurotransmitter interactions using positron emission tomography and functional coupling. Clin Neuropharmacol 1996;19(5):371-89.
  55. Fields RD, Stevens-Graham B. New insights into neuron-glia communication. Science 2002;298(5593):556-62.
  56. Eroglu C, Barres BA. Regulation of synaptic connectivity by glia. Nature 2010;468(7321):223-31.
  57. Perea G, Araque A. GLIA modulates synaptic transmission. Brain Res Rev 2010;63(1-2):93-102.
  58. Pannasch U, Vargová L, Reingruber J, et al. Astroglial networks scale synaptic activity and plasticity. Proc Natl Acad Sci U S A 2011;108(20):8467-72.
  59. López-Muñoz F, Alamo C. Historical evolution of the neurotransmission concept. J Neural Transm 2009;116(5):515-33.
  60. Llewellyn-Smith IJ. Anatomy of synaptic circuits controlling the activity of sympathetic preganglionic neurons. J Chem Neuroanat 2009;38(3):231-9.
  61. Mulè F, Amato A, Baldassano S, Serio R. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol Res 2007;56(2):132-9.
  62. El-Mahmoudy A, Matsuyama H, Khalifa M, Shimizu Y, Takewaki T. Tachykinins mediate non-adrenergic, non-cholinergic excitatory neurotransmission to the hamster ileum via NK1 and NK2 receptors. Life Sci 2003;73(15):1939-51.
  63. Elde R, Arvidsson U, Riedl M, et al. Distribution of neuropeptide receptors. New views of peptidergic neurotransmission made possible by antibodies to opioid receptors. Ann N Y Acad Sci 1995;757:390-404.
  64. van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003;480(1-3):133-50.
  65. Rand MJ. Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission. Clin Exp Pharmacol Physiol 1992;19(3):147-69.
  66. Bustamante S, Orensanz LM, Recio P, Carballido J, García-Sacristán A, Prieto D, Hernández M. Functional evidence of nitrergic neurotransmission in the human urinary bladder neck. Neurosci Lett 2010;477(2):91-4.
  67. Zhang Z, Bhalla A, Dean C, Chapman ER, Jackson MB. Synaptotagmin IV: a multifunctional regulator of peptidergic nerve terminals. Nat Neurosci 2009;12(2):163-71.
  68. Frank RT, Aboody KS, Najbauer J. Strategies for enhancing antibody delivery to the brain. Biochim Biophys Acta 2011;1816(2):191-8.
  69. Drlicek M, Liszka U, Jellinger K, Mohn-Staudner A, Lintner F, Grisold W. Circulating antineuronal antibodies reach neurons in vivo: an autopsy study. J Neurol 1992;239(7):407-10.
  70. Sas A, Jones R, Tyor W. Intra-peritoneal injection of polyclonal anti-interferon alpha antibodies cross the blood brain barrier and neutralize interferon alpha. Neurochem Res 2008;33(11):2281-7.
  71. Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, Nagele RG. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 2010;1345:221-32.
  72. Xiao BG, Link H. Immune regulation within the central nervous system. J Neurol Sci 1998 Apr 15;157(1):1-12.
  73. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature 2010;468(7321):253-62.
  74. Man S, Tucky B, Cotleur A, Drazba J, Takeshita Y, Ransohoff RM. CXCL12-Induced Monocyte-Endothelial Interactions Promote Lymphocyte Transmigration Across an in Vitro Blood-Brain Barrier. Sci Transl Med 2012 Feb 1;4(119):119ra14. DOI: 10.1126/scitranslmed.3003197.
  75. Knopf PM, Harling-Berg CJ, Cserr HF, et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol 1998;161(2):692-701.
  76. Raiteri M, Bertollini A, La Bella R. Synaptosome antisera affect permeability of synaptosomal membranes in vitro. Nat New Biol 1972;238(86):242-3.
  77. Raiteri M, Levi G. Antisynaptosome antibodies affect synaptosomal permeability to neurotransmitters. Nat New Biol 1973;245(142):89-91.
  78. Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: a historical point of view. Anat Rec B New Anat 2006;289(1):3-8.
  79. Ohtsuki S. New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system. Biol Pharm Bull 2004;27(10):1489-96.
  80. Johansson PA, Dziegielewska KM, Liddelow SA, Saunders NR. The blood-CSF barrier explained: when development is not immaturity. Bioessays 2008;30(3):237-48.
  81. Banks WA. The blood-brain barrier in psychoneuroimmunology. Neurol Clin 2006;24(3):413-9.
  82. Banks WA. Blood-brain barrier as a regulatory interface. Forum Nutr 2010;63:102-10.
  83. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37(1):13-25.
  84. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009;31(4):497-511.
  85. Dankbaar JW, Hom J, Schneider T, Cheng SC, Lau BC, van der Schaaf I, Virmani S, Pohlman S, Wintermark M. Age- and anatomy-related values of blood-brain barrier permeability measured by perfusion-CT in non-stroke patients. J Neuroradiol 2009;36(4):219-27.
  86. Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 2011;585(23):3770-80.
  87. Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, Antel JP. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181(8):5730-7.
  88. Kanda T, Yamawaki M, Iwasaki T, Mizusawa H. Glycosphingolipid antibodies and blood-nerve barrier in autoimmune demyelinative neuropathy. Neurology 2000;54(7):1459-64.
  89. Faust TW, Chang EH, Kowal C, et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A 2010;107(43):18569-74.
  90. Whitney KD, McNamara JO. Autoimmunity and neurological disease: antibody modulation of synaptic transmission. Annu Rev Neurosci 1999;22:175-95.
  91. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8(5):475-90.
  92. Vaknin-Dembinsky A, Abramsky O, Petrou P, et al. Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Arch Neurol 2011 Dec;68(12):1557-61.
  93. Miyazaki Y, Hirayama M, Watanabe H, Usami N, Yokoi K, Watanabe O, Sobue G. Paraneoplastic encephalitis associated with myasthenia gravis and malignant thymoma. J Clin Neurosci 2012 Feb;19(2):336-8.
  94. Wang Z, Low PA, Jordan J, et al. Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology 2007;68(22):1917-21.
  95. Vernino S. Neuronal acetylcholine receptor autoimmunity. Ann N Y Acad Sci 2008;1132:124-8.
  96. Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010;168(4):1009-18.
  97. Sárvári M, Kalló I, Hrabovszky E, et al. Estradiol replacement alters expression of genes related to neurotransmission and immune surveillance in the frontal cortex of middle-aged, ovariectomized rats. Endocrinology 2010;151(8):3847-62.
  98. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr Pharm Des 2005;11(8):1017-30.
  99. Appenzeller S, Costallat LT, Cendes F. Neurolupus. Arch Neurol 2006;63(3):458-60.
  100. Irani SR, Vincent A. Autoimmune encephalitis -- new awareness, challenging questions. Discov Med 2011;11(60):449-58.
  101. Graus F, Dalmau J. CNS autoimmunity: new findings and pending issues. Lancet Neurol 2012;11(1):17-9.
  102. Barry H, Hardiman O, Healy DG, et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry 2011;199(6):508-9.
  103. Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci 2011;23(1):90-7.
  104. Tanaka S, Matsunaga H, Kimura M, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003;141(1-2):155-64.
  105. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011;168(12):1303-10.
  106. Zandi MS, Irani SR, Lang B, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011;258(4):686-8.
  107. Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010;167(9):1039-50.
  108. Padmos RC, Bekris L, Knijff EM, et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry 2004;56(7):476-82.
  109. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011;24(6):519-25.
  110. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2011;14(7):997-1012.
  111. Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2008 May;29(9):1110-7.
  112. Ganguli A, Fitzgerald R, Walker L, Beadsworth M, Mwandumba HC. Voltage-gated, potassium-channel antibody-associated limbic encephalitis presenting as acute psychosis. J Neuropsychiatry Clin Neurosci 2011;23(2):E32-4.
  113. Haddad JJ, Saadé NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol 2002;133(1-2):1-19.
  114. Haddad JJ. On the mechanisms and putative pathways involving neuroimmune interactions. Biochem Biophys Res Commun 2008;370(4):531-5.
  115. Huang D, Han Y, Rani MR, et al. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev. 2000;177:52-67.
  116. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol 2006;79(6):1093-104.
  117. Fischer EG. Opioid peptides modulate immune functions. A review. Immunopharmacol Immunotoxicol 1988;10(3):265-326.
  118. Matsuda T, Yamasaki K, Taga T, Hirano T, Kishimoto T. Current concepts of B cell modulation. Int Rev Immunol 1989;5(2):97-109.
  119. Madden KS, Sanders VM, Felten DL. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol 1995;35:417-48.
  120. Qiu Y, Peng Y, Wang J. Immunoregulatory role of neurotransmitters. Adv Neuroimmunol 1996;6(3):223-31.

Lascia la tua opinione

* campi obbligatori (l'indirizzo email NON verrà pubblicato)